Skip to content

TO STUDY IF THE USE OF ADENOSINE IN CONGENITAL HEART SURGERY HAS A PROTECTIVE EFFECT OVER THE HEART FUNCTION

CARDIOPROTECTIVE ROLE OF ADENOSINE IN CONGENITAL CARDIAC SURGERY-A DOUBLE BLINDED RANDOMISED TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015385
Enrollment
70
Registered
2018-08-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I52- Other heart disorders in diseasesclassified elsewhere Health Condition 2: null- Patients of pediatric age group with congenital cardiac defects weighing less than 20 kgs

Interventions

Intervention1: Adenosine: After initiation of cardio-pulmonary bypass, a bolus dose of Adenosine is given through the aortic root just before application of aortic cross Clamp and administration of c

Sponsors

DirectorAIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients below 20 kgs of weight undergoing elective repair of complex congenital heart defects with aortic cross clamp times of greater than 45 minutes will be recruited in this study

Exclusion criteria

Exclusion criteria: 1.Patients with isolated ASD,isolated pulmonary stenosis or patients with Bi-directional Cavo-pulmonary shunt undergoing Fontan completion. 2.Patients with chromosomal defects 3.Airway and parenchymal disease 4.Immunodeficiency or blood disorders 5.Emergency surgery 6.Parents/guardians not willing to given consent to participate in the study

Design outcomes

Primary

MeasureTime frame
To compare the Cardiac Index in these groups in the post operative period To assess and compare the presence of arrhythmias in the post-operative ICU period in these groupsTimepoint: During the period of admission at the hospital

Secondary

MeasureTime frame
1. To compare the duration of ICU stay in these groups 2.To assess and compare the surrogates of myocardial protection in the form of A.Cardiac enzyme release B.Decreased urine output C.use of inotropes in the post-operative periodTimepoint: During the period of admission at the hospital

Countries

India

Contacts

Public ContactDr Sachin Talwar

All India Institute of Medical Sciences,New Delhi

sachintalwar@hotmail.com9868398136

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026